"studyAcronym","id","studyTitle","studyVersion","studyRationale","uuid:ID"
"LZZT","StudyVersion_1","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","00b4e1bb-f973-44b0-aa92-be32070cb13e"
